Horizon Discovery Group (HZNQF) Stock Price, News & Analysis

Company Overview

Horizon Discovery Group is a biotechnology company specializing in gene editing and gene modulation technologies for research and therapeutic development. The company provides a suite of engineered cell line models and related services that enable scientists to investigate gene function, validate drug targets and develop novel therapies. Its core offerings include CRISPR/Cas9–based genome editing, zinc finger nuclease platforms and RNA interference tools, designed to address critical questions in oncology, immunology and rare genetic diseases.

In addition to off-the-shelf cell lines with specific genetic alterations, Horizon Discovery offers custom cell line engineering, assay development and companion diagnostic support through its comprehensive cell model portfolio. The company’s CRO-style services cover target identification and validation, mechanism-of-action studies, high-throughput screening support and biomarker discovery. These capabilities aim to accelerate preclinical research and streamline the transition from early discovery to clinical development for pharmaceutical and biotechnology customers.

Founded in 2008 and headquartered in Cambridge, United Kingdom, Horizon Discovery has built a global presence with additional facilities in the United States, Europe and Asia. In 2021, the company was acquired by PerkinElmer, becoming part of its life sciences division. This integration has expanded Horizon Discovery’s reach and resources, enhancing its ability to serve a broad array of academic, biotech and pharmaceutical clients worldwide.

Serving research institutions and commercial organizations across North America, Europe and Asia, Horizon Discovery leverages its technical expertise and large-scale manufacturing capacity to deliver reproducible, quality-controlled cell models. Its work supports critical stages of drug discovery and development, enabling customers to reduce timelines, lower costs and improve the predictive value of preclinical studies.

Key Stats

• Today's Range: $2.45 to $2.45
• 50-Day Range: $2.45 to $2.45
• 52-Week Range: $1.20 to $2.54
• Volume: N/A
• Average Volume: 25,763 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HZNQF
• CIK: N/A
• Web: www.horizondiscovery.com
• Phone: 44 1223 976 000
• Fax: N/A
• Employees: 416
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A